Cited by 347Immunotherapy and Immune ResponsesSARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

The DOI matches its Crossref record; 147 of the 151 references it cites were found in a registry or an index.

Novel approaches for vaccine development

Open access

Gebre, Makda S., Brito, Luis A., Tostanoski, Lisa H., Edwards, Darin K., Carfi, Andrea, Barouch, Dan H.·2021·Cell

DOI 10.1016/j.cell.2021.02.030PMC PMC8049514

Open this paper in CoChat — free account Open PDF

Abstract

Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.02.030

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 3×
“Lipid nanoparticle mRNA delivery In contrast to naked mRNA, formulated mRNA has been shown to result in higher protein expression in vitro and more potent immune responses in vivo (Pollard et al., 2013; Wolff et al., 1990).”
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 4×
“mRNA-1273 vaccine candidates, both encoding the SARS-CoV-2 pre-fusion stabilized S2P protein, which showed very high efficacy in Phase 3 trials (Baden et al., 2020a; Jackson et al., 2020; Mulligan et al., 2020; Polack et al., 2020).”
Influential
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419

Flagged first, then by citations

Show all 151 references

4 of the 151 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Goldstein, 2020, Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study, J. Infect. Dis.
Mulligan, 2020, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature, 586, 589, 10.1038/s41586-020-2639-4 · DOI · Paper page
Sadoff, 2020, Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial, medRxiv

Sorted by citations

Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Recent advances in regenerative biomaterials
Cao, D., & Ding, J. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac098 · Cited by 277
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. K. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 276
Lipid nanoparticles in the development of mRNA vaccines for COVID-19
Wilson, B., & Geetha, K. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103553 · Cited by 265
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Cai, Y., Zhang, J., Xiao, T., Lavine, C. L., Rawson, S., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., et al. (2021) · Science · doi:10.1126/science.abi9745 · Cited by 222
COVID-19 vaccination: The road ahead
Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 198
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172
Synthetic Biology: Bottom-Up Assembly of Molecular Systems
Hirschi, S., Ward, T. R., Meier, W. P., Müller, D. J., & Fotiadis, D. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00339 · Cited by 152
An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice
Nanishi, E., Borriello, F., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Seo, H., van Haren, S. D., Cavazzoni, C. B., Brook, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5305 · Cited by 123
Self-citation
DC-Derived Exosomes for Cancer Immunotherapy
Yao, Y., Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2021) · Cancers · doi:10.3390/cancers13153667 · Cited by 117
Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics
Mukai, H., Ogawa, K., Kato, N., & Kawakami, S. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100450 · Cited by 108
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 112
The advances of adjuvants in mRNA vaccines
Xie, C., Yao, R., & Xia, X. (2023) · npj Vaccines · doi:10.1038/s41541-023-00760-5 · Cited by 102
Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response
Zhang, J., Wang, S., Guo, X., Lu, Y., Liu, X., Jiang, M., Li, X., Qin, B., Luo, Z., Liu, H., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05408 · Cited by 89
Advanced technologies for the development of infectious disease vaccines
Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 87
Biomimetic Exosomes: A New Generation of Drug Delivery System
Wang, X., Zhao, X., Zhong, Y., Shen, J., & An, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.865682 · Cited by 79
Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
Duan, L.-J., Wang, Q., Zhang, C., Yang, D.-X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923647 · Cited by 83
COVID-19 Vaccines: Adenoviral Vectors
Jacob-Dolan, C., & Barouch, D. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-012621-102252 · Cited by 76
Self-citation
Engineered Cell Membrane‐Derived Nanoparticles in Immune Modulation
Yang, Y., Wang, K., Pan, Y., Rao, L., & Luo, G. (2021) · Advanced Science · doi:10.1002/advs.202102330 · Cited by 78
Advances in the polymeric delivery of nucleic acid vaccines
Chen, G., Zhao, B., Ruiz, E. F., & Zhang, F. (2022) · Theranostics · doi:10.7150/thno.70853 · Cited by 76
Vaccine Strategies to Elicit Mucosal Immunity
Song, Y., Mehl, F., & Zeichner, S. L. (2024) · Vaccines · doi:10.3390/vaccines12020191 · Cited by 87
Controversy surrounding the Sputnik V vaccine
Cazzola, M., Rogliani, P., Mazzeo, F., & Matera, M. G. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106569 · Cited by 66
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 67
Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines
Russell, C. A., Fouchier, R. A. M., Ghaswalla, P. K., Park, Y., Vicic, N., Ananworanich, J., Nachbagauer, R., & Rudin, D. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2336357 · Cited by 69
Mannose in vaccine delivery
Nahar, U. J., Tóth, I., & Skwarczyński, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.038 · Cited by 65
Host Responses to Respiratory Syncytial Virus Infection
Agac, A., Kolbe, S. M., Ludlow, M., Osterhaus, A. D. M. E., Meineke, R., & Rimmelzwaan, G. F. (2023) · Viruses · doi:10.3390/v15101999 · Cited by 72
Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice
Wang, Y. X., Zhang, J., Liu, Y., Xiao, Y., Han, K. S., Kong, Z., Dong, Y., Yang, Z., Fu, Z., Tang, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4791 · Cited by 68
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
Conforti, A., Marra, E., Palombo, F., Roscilli, G., Ravà, M., Fumagalli, V., Muzi, A., Maffei, M., Luberto, L., Lione, L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.011 · Cited by 55
Bioengineered nanotechnology for nucleic acid delivery
Zhang, Y., Luo, J., Gui, X., Zheng, Y., Schaar, E., Liu, G., & Shi, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.034 · Cited by 65
Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential
Ho, M. Y., Liu, S., & Xing, B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00434-5 · Cited by 62
Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications
Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 64
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 59
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Components, Formulations, Deliveries, and Combinations of Tumor Vaccines
Liu, T., Yao, W., Sun, W., Yuan, Y., Liu, C., Liu, X., Wang, X., & Jiang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05065 · Cited by 57
Rational development of a combined mRNA vaccine against COVID-19 and influenza
Ye, Q., Wu, M., Chao Hui, Z. H. O. U., Lu, X., Huang, B., Zhang, N., Zhao, H. J., Chi, H., Zhang, X., Ling, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00478-w · Cited by 51
Bioresponsive Immunotherapeutic Materials
Han, J., Sheng, T., Zhang, Y., Cheng, H., Gao, J., Yu, J., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202209778 · Cited by 52
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45
A Polyvalent Peptide CD40 Nanoagonist for Targeted Modulation of Dendritic Cells and Amplified Cancer Immunotherapy
Mamuti, M., Wang, Y., Zhao, Y., Wang, J., Wang, J., Fan, Y., Xiao, W., Hou, D., Yang, J., Zheng, R., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109432 · Cited by 49
Development of Nasal Vaccines and the Associated Challenges
Nian, X., Zhang, J., Huang, S., Duan, K., Li, X., & Yang, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101983 · Cited by 52
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
Chen, L., Qu, J., Kalyani, F. S., Zhang, Q., Fan, L., Fang, Y., Li, Y., & Xiang, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04096-y · Cited by 47
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
In Silico Studies to Support Vaccine Development
Saldanha, L., Langel, Ü., & Vale, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020654 · Cited by 41
COVID-19 vaccines: Immune correlates and clinical outcomes
Mahrokhian, S. H., Tostanoski, L. H., Vidal, S. J., & Barouch, D. H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2324549 · Cited by 43
Self-citation
RETRACTED: New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
Fragoso, Y. D., Gomes, S., Gonçalves, M. V. M., Júnior, E. M., de Oliveira, B. E. S., Rocha, C. F., dos Santos, G. A. C., Tauil, C. B., Araujo, R. V., & Peron, J. P. S. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103321 · Cited by 38
Retracted
Autoimmune hepatitis after COVID-19 vaccination
Han, Z., Zhang, T., Xu, Y., Lu, X. B., & Sang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035073 · Cited by 42
Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges
Qiu, L., Chirman, D. M., Clark, J. R., Xing, Y., Santos, H. H., Vaughan, E. E., & Maresso, A. W. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2359691 · Cited by 41
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery
Khan, M. S., Appak‐Baskoy, S., Yang, C. J., Hong, J., Chae, J., Ha, H.-J., Lee, S., Tanaka, M., Choi, Y., & Choi, J. H. (2023) · Nanoscale Advances · doi:10.1039/d2na00795a · Cited by 37
Umbilical artery acid-base status in the preterm infant.
Ramin, S. M., Gilstrap, L. C., Leveno, K. J., Burris, J., & Little, “. B. B. (1989) · PubMed · Cited by 37
Analytical Characterization of Heterogeneities in mRNA-Lipid Nanoparticles Using Sucrose Density Gradient Ultracentrifugation
Vaidya, A. M., Parande, D., Khadse, N., Vargas‐Montoya, N., Agarwal, V., Ortiz, C., Ellis, G., Kaushal, N., Sarode, A., Karve, S., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00031 · Cited by 37
Vaccine innovation model: A technology transfer perspective in pandemic contexts
Medeiros, M. Z., Soares, P. F., Fialho, B. D. C., Gauss, L., Piran, F. S., & Lacerda, D. P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.054 · Cited by 38
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33
Vaccine development using artificial intelligence and machine learning: A review
Asediya, V., Anjaria, P. A., Mathakiya, R. A., KORINGA, P. G., Nayak, J. B., Bisht, D., Fulmali, D., Patel, V. A., & Desai, D. N. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136643 · Cited by 35
Nanovaccines against Animal Pathogens: The Latest Findings
Celis-Giraldo, C. T., López‐Abán, J., Muro, A., Patarroyo, M. A., & Manzano-Román, R. (2021) · Vaccines · doi:10.3390/vaccines9090988 · Cited by 35
Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects
Farhana, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043493 · Cited by 33
In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD
Shi, J., Zhu, Y., Yin, Z., He, Y., Li, Y., Haimiti, G., Xie, X., Niu, C., Guo, W., & Zhang, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-57793-6 · Cited by 34
mRNA vaccines induce rapid antibody responses in mice
Gebre, M. S., Rauch, S., Roth, N., Gergen, J., Yu, J., Liu, X., Cole, A. C., Mueller, S. O., Petsch, B., & Barouch, D. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00511-y · Cited by 32
Self-citation
Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds
Lamontagne, F., Khatri, V., St‐Louis, P., Bourgault, S., & Archambault, D. (2022) · Vaccines · doi:10.3390/vaccines10111920 · Cited by 34
mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation
Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 36
Nanoparticles and Antiviral Vaccines
Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 35
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview
Henríquez, R., & Muñoz‐Barroso, I. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34927 · Cited by 32
The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women
Wang, P., Lee, W.-L., Yang, S., Tsui, K., Chang, C., & Lee, F. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000612 · Cited by 31
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
Valentin, A., Bergamaschi, C., Rosati, M., Angel, M., Burns, R., Agarwal, M., Gergen, J., Petsch, B., Oostvogels, L., Loeliger, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945706 · Cited by 32
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
Chai, Q., Li, D., Zhang, M., Gu, Y., Li, A., Wu, X., Liu, X., & Liu, J. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101277 · Cited by 32
Sustainable vaccine manufacturing in low- and middle-Income countries
Hayman, B., Suri, R. K., & Downham, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.044 · Cited by 32
mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines
Zhivaki, D., Gosselin, E. A., Sengupta, D., Concepcion, H. A., Arinze, C., Chow, J., Nikiforov, A., Komoroski, V., MacFarlane, C., Sullivan, C., et al. (2023) · mBio · doi:10.1128/mbio.02506-23 · Cited by 31
Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19
Iqbal, S. M., Rosen, A. M., Edwards, D. K., Bolio, A., Larson, H. J., Servin, M., Rudowitz, M., Carfı́, A., & Ceddia, F. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1429265 · Cited by 30
Self-citation
Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00370-1 · Cited by 29
mRNA Vaccine Nanoplatforms and Innate Immunity
Wei, L., Dong, C., Zhu, W., & Wang, B. (2024) · Viruses · doi:10.3390/v16010120 · Cited by 28
Engineering customized nanovaccines for enhanced cancer immunotherapy
Guo, J., Liu, C., Qi, Z., Qiu, T., Zhang, J. C., & Yang, H. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.02.028 · Cited by 27
Vaccine design and development: Exploring the interface with computational biology and AI
Ananya, A., Panchariya, D. C., Karthic, A., Singh, S. P., Mani, A., Chawade, A., & Kushwaha, S. K. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2374546 · Cited by 30
Advances in mRNA vaccines
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 30
Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach
Bu, T., Yang, W., Zhao, J., Gao, Y., Li, F., & Yang, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010379 · Cited by 32
Breast cancer vaccines for treatment and prevention
Disis, M. L., & Cecil, D. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06459-2 · Cited by 26
An Adenovirus‐Mimicking Photoactive Nanomachine Preferentially Invades and Destroys Cancer Cells through Hijacking Cellular Glucose Metabolism
Zhang, Y., Feng, S., Hu, G., Fang, T., Xie, D., Lu, Q., Xu, Y., Shen, L., & Ning, X. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202110092 · Cited by 26
Supramolecular biomaterials for enhanced cancer immunotherapy
Zhang, H., Zhu, J., Fang, T., Li, M., Chen, G., & Chen, Q. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00048b · Cited by 26
Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer
Sanya, D. R. A., Cava, C., & Onésime, D. (2022) · Human Cell · doi:10.1007/s13577-022-00843-w · Cited by 26
Exosome may be the next generation of promising cell-free vaccines
Dai, Z., Cai, R., Zeng, H., Zhu, H., Dou, Y., & Sun, S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2345940 · Cited by 26
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies
Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 28
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions
Hsiung, K. C., Chiang, H.-J., Reinig, S., & Shih, S. (2024) · Vaccines · doi:10.3390/vaccines12121345 · Cited by 25
A tale of nucleic acid–ionizable lipid nanoparticles: Design and manufacturing technology and advancement
De, A., & Ko, Y. T. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2153832 · Cited by 24
Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections
Sauvat, L., Verhoeven, P. O., Gagnaire, J., Berthelot, P., Paul, S., Botelho-Nevers, É., & Gagneux‐Brunon, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00160-22 · Cited by 24
Microfluidics for Nanomedicine Delivery
Chen, K., Yang, H., & Cai, R. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02052 · Cited by 25
Use of Bacterial Extracellular Vesicles for Gene Delivery to Host Cells
Kim, S.-I., Ha, J. Y., Choi, S., Hong, S., & Lee, H. (2022) · Biomolecules · doi:10.3390/biom12091171 · Cited by 22
3D DNA origami pincers that multitask on giant unilamellar vesicles
Zhan, P., Yang, J., Ding, L. L., Jing, X., Hipp, K., Nußberger, S., Yan, H., & Liu, N. (2024) · Science Advances · doi:10.1126/sciadv.adn8903 · Cited by 21
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
TransMA: an explainable multi-modal deep learning model for predicting properties of ionizable lipid nanoparticles in mRNA delivery
Wu, K., Wang, Z., Yang, X., Chen, Y., Mastrogiovanni, F., Zhang, J., & Liu, L. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf307 · Cited by 23
Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus
Malik, S., Sah, R., Ahsan, O., Muhammad, K., & Waheed, Y. (2023) · Vaccines · doi:10.3390/vaccines11020325 · Cited by 21
Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review
Patil, S., Singh, I. P., Verma, I. K., Kumar, A., Sharma, J., Ratn, A., Dhakad, M. S., & Sharma, D. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s544665 · Cited by 22
Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges
Ding, Y., Xue, M., Tang, Q., Wang, L., Ding, H.-Y., Li, H., Gao, C., & Yu, W. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i37.5403 · Cited by 21
Vetinformatics from functional genomics to drug discovery: Insights into decoding complex molecular mechanisms of livestock systems in veterinary science
Pathak, R. K., & Kim, J. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1008728 · Cited by 22
Lipid-mRNA nanoparticles landscape for cancer therapy
Li, Y., Fang, H., Zhang, T., Wang, Y., Qi, T., Li, B., & Jiao, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1053197 · Cited by 20
A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov
Wang, S., Liu, W.-Q., Li, Y., Li, J., & Zhu, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2242528 · Cited by 18
Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review
Malik, S., Asghar, M., & Waheed, Y. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100452 · Cited by 19
Recent development of oral vaccines (Review)
Liu, Y., Lam, D. M., Luan, M., Zheng, W., & Ai, H. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12511 · Cited by 18
Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines
Li, Y., Xu, Y., Su, W., Xu, J., Ye, Z., Wang, Z., Liu, Q., & Chen, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117897 · Cited by 18

Authors: Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H.
Affiliations: Beth Israel Deaconess Medical Center (US)
Moderna Therapeutics (United States) (US)
Corresponding author: Barouch, Dan H.
ORCID: Gebre, Makda S.
Tostanoski, Lisa H.
Edwards, Darin K.
Barouch, Dan H.
Venue: Cell
Publisher: Elsevier BV
Published: 2021-03
Volume: 184
Issue: 6
Pages: 1589-1603
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2021.02.030
PMC: PMC8049514
OpenAlex: W3137746616
Cited by: 347
References: 151
Citations by year: 2026: 42 · 2025: 92 · 2024: 72 · 2023: 55 · 2022: 63 · 2021: 21
FWCI: 5.41
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 383 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (U01CA260476)
National Institute of Allergy and Infectious Diseases (U19AI128751, T32AI007387)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: vaccine development, RNA vaccines, nucleic acid vaccines, viral vector vaccines, recombinant adenovirus vector, persistent infection, emerging pathogens, biomaterials
MeSH terms: Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Adenoviridae, Animals, Antigens, Viral, Biocompatible Materials, Genetic Vectors, Humans, Liposomes, RNA, Messenger, Vaccines, Synthetic, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel approaches for vaccine development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks